Opportunistic screening for lung cancer helped lower the risk of death related to the disease in China. Low-dose computed tomography can reduce the number of deaths from lung cancer in Brazil. The use of tobacco negatively affects survival outcomes in patients with advanced NSCLC. Patients with EGFR-positive metastatic NSCLC whose disease progressed following first-line treatment have worse outcomes. Patient selection for perioperative immunotherapies may be determined by specific intratumoral immune cells. A study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as neoadjuvant treatment. Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood. The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC. The DeLLphi-301 study that evaluated patients with advanced SCLC. Arun Krishna, of AstraZeneca, talks about the LAURA Phase III trial, which assessed Tagrisso in NSCLC patients. Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC. A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC. Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control. Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC. A complete residential history should be reviewed following a mesothelioma diagnosis. Patients with lung cancer who were treated with ICIs and developed TRL had poorer survival outcomes. Individuals with poor sleep quality are more likely to get lung cancer than those with good sleep quality. Bronchoalveolar lavage supernatant may serve as a possible target in early-stage lung cancer research, a recent study showed. Researchers created a novel prediction model that can forecast OS in patients with adenocarcinoma. Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.